Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Completed
Conditions studied: Lung Cancer
In brief
This research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy. Prognostic markers are patient or tumor factors that predict patient survival independent of treatment. Predictive markers are factors that may influence and predict the outcome of treatment in terms of either response or survival benefit. Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.
Key facts
- Study ID
- NCT01294280
- Run by
- Alliance for Clinical Trials in Oncology
- People needed
- 241
- Starts
- 2008-07-01
- Expected to finish
- 2016-02-02
- Last updated by the study team
- 2021-01-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Registration to CALGB9633 for this study
- Institutional Review Board (IRB) review and approval at the institution where the laboratory work will be performed is required
- Informed consent:
- The subject population to be studied in this protocol includes patients selected from CALGB 9633 for whom an available specimen is present at the Alliance Ohio State University (OSU); all such patients have signed a written informed consent document meeting all federal, state, and institutional guidelines as part of entry into that trial
- Only cases with adequate tumor formalin FFPE material without depleting the available clinical block(s) are eligible
Where it is running
- SUNY Upstate Medical University — Syracuse, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.